Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
PETALUMA, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
PETALUMA, Calif. , April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions and advanced tissue care, today announced it has
View HTML
Toggle Summary Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution
PETALUMA, Calif. , March 27, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today launched a
View HTML
Toggle Summary Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
PETALUMA, Calif. , March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants - SNOAW) today announced that Jim Schutz , Sonoma CEO, will be a featured presenter at the Roth Capital Partners 30th Annual Growth Stock Conference on Tuesday, March 13, 2018 at 3:00 pm PDT in
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock
PETALUMA, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals , Inc. (Nasdaq: SNOA, Warrants - SNOAW) today announced the closing of a public offering of 1,428,570 shares of common stock at a public offering price of $3.50 per share. The net proceeds to Sonoma Pharmaceuticals, Inc.
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock
PETALUMA, Calif. , March 02, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants - SNOAW) today announced the pricing of a "best efforts" public offering of up to 1,428,571 shares of common stock at a public offering price of $3.50 per share.
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
Product revenue up 12% compared to September 2017 quarter U.S. product revenue up 27% compared to the September 2017 quarter Cash on hand equals $8.6 million at quarter end Conference Call Begins at 4:30pm EST Today Slide Presentation to Review in Tandem with Earnings Call Available at
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW) today announced that financial results for its fiscal third quarter 2018, ended December 31, 2017 , will be released after the U.S. markets close on February 7, 2018 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis
PETALUMA, Calif. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis
Second FDA approval in as many months further validates expanding adoption of Alevicyn products by dermatologists
View HTML